UC2GM137435
Cooperative Agreement
Overview
Grant Description
SPAD at Kennesaw State University - In response to RFA-RM-19-004: Sponsored Programs Administration Development (SPAD), we propose to establish the SPAD at Kennesaw State University (KSU) program. KSU is a rapidly growing and the 3rd largest university in the University System of Georgia (USG), primarily serving undergraduates (~35,000) from diverse (>35% URM), and lower socioeconomic status (~36% of students are Pell-eligible) backgrounds.
In its nascent stage of development, KSU’s research enterprise is small (~$1.68M in total NIH RPG funding over the past three fiscal years); yet through the NIH Bridges to the Doctorate program and other recent programming, KSU shows amazing promise in its ability to impact research with primarily undergraduate students.
Based on an in-depth self-assessment of the research challenges faced by KSU, the goals of the SPAD at KSU program are timely, relevant, and strategic. We propose to:
A) Develop capacity for both under-represented minority (URM) faculty and students to conduct biomedical research;
B) Develop our sponsored programs and diversity infrastructures to support the growing research emphasis of the university; and
C) Develop linkages and collaborations across the state and region to increase our competitiveness in biomedical research.
To achieve these goals, we have identified 28 activities that the SPAD at KSU program proposes to launch, with strategic and intentional guidance from a steering committee, key mentors representing KSU aspirational institutions, and expert consultants. These activities range from development of best practice procedures and policies for grants management, to explicit mentoring and research development activities for URM faculty and students, to the strengthening of key regional and national partnerships in biomedical research.
The success of the SPAD at KSU program will be transformative in changing the research culture at KSU. We expect to positively impact the growth of research development and to develop a solid and sustainable grants administration foundation. Faculty and students, particularly URM, will be empowered to conduct research with relevance, and the institution will have built a strong internal infrastructure as well as linkages and collaborations across the state and region to increase our competitiveness in biomedical research.
In its nascent stage of development, KSU’s research enterprise is small (~$1.68M in total NIH RPG funding over the past three fiscal years); yet through the NIH Bridges to the Doctorate program and other recent programming, KSU shows amazing promise in its ability to impact research with primarily undergraduate students.
Based on an in-depth self-assessment of the research challenges faced by KSU, the goals of the SPAD at KSU program are timely, relevant, and strategic. We propose to:
A) Develop capacity for both under-represented minority (URM) faculty and students to conduct biomedical research;
B) Develop our sponsored programs and diversity infrastructures to support the growing research emphasis of the university; and
C) Develop linkages and collaborations across the state and region to increase our competitiveness in biomedical research.
To achieve these goals, we have identified 28 activities that the SPAD at KSU program proposes to launch, with strategic and intentional guidance from a steering committee, key mentors representing KSU aspirational institutions, and expert consultants. These activities range from development of best practice procedures and policies for grants management, to explicit mentoring and research development activities for URM faculty and students, to the strengthening of key regional and national partnerships in biomedical research.
The success of the SPAD at KSU program will be transformative in changing the research culture at KSU. We expect to positively impact the growth of research development and to develop a solid and sustainable grants administration foundation. Faculty and students, particularly URM, will be empowered to conduct research with relevance, and the institution will have built a strong internal infrastructure as well as linkages and collaborations across the state and region to increase our competitiveness in biomedical research.
Awardee
Grant Program (CFDA)
Place of Performance
Georgia
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 199% from $270,898 to $809,622.
Kennesaw State University was awarded
SPAD at Kennesaw State University
Cooperative Agreement UC2GM137435
worth $809,622
from the National Institute of Allergy and Infectious Diseases in May 2021 with work to be completed primarily in Georgia United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not Allowed).
Status
(Complete)
Last Modified 4/27/23
Period of Performance
5/18/21
Start Date
4/30/24
End Date
Funding Split
$809.6K
Federal Obligation
$0.0
Non-Federal Obligation
$809.6K
Total Obligated
Activity Timeline
Transaction History
Modifications to UC2GM137435
Additional Detail
Award ID FAIN
UC2GM137435
SAI Number
UC2GM137435-643592824
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NS00 NIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
V1WUYJCYJVJ4
Awardee CAGE
3CWC4
Performance District
11
Senators
Jon Ossoff
Raphael Warnock
Raphael Warnock
Representative
Barry Loudermilk
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Office of the Director, National Institutes of Health, Health and Human Services (075-0846) | Health research and training | Grants, subsidies, and contributions (41.0) | $538,724 | 100% |
Modified: 4/27/23